Skip to main content

Day: February 28, 2022

Newtek Business Services Corp. to Provide Update on its Acquisition of National Bank of New York City on Wednesday, March 2, 2022 at 8:30 am ET

BOCA RATON, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (Nasdaq: NEWT), an internally managed business development company (“BDC”), today announced that Barry Sloane, Chief Executive Officer will host a conference call with a corresponding presentation on Wednesday, March 2, 2022, at 8:30 am ET to provide an update on the pending acquisition of the National Bank of New York City, with revised illustrations. The live conference call can be accessed by dialing (877) 303-6993 or (760) 666-3611. A live webcast of the call and the corresponding presentation will be available in the ‘Events & Presentations’ section of the Investor Relations portion of Newtek’s website at http://investor.newtekbusinessservices.com/events-and-presentations. The presentation will be available on Newtek’s website beginning...

Continue reading

Šiaulių bankas will hold an Investor Conference Webinar to introduce the financial results for 2021 and recent developments

AB Šiaulių bankas invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the March 2, 2022 at 4 pm (EET). The presentation will be held in English. The webinar will be hosted by Vytautas Sinius, CEO and Donatas Savickas, CFO who will introduce the Bank’s financial results for 2021 and recent developments, as well participants questions will be answered. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until March 2, 1 pm to emilija.ivanauskaite@nasdaq.com. How to join the webinar? To join the webinar, please register via following link:https://register.gotowebinar.com/register/7792731908536523021. You will be provided with the webinar link and instructions how to...

Continue reading

Magnite Acquires Carbon to Accelerate Publisher Audience Activation

Team to contribute to audience and identity tools across CTV, mobile and display NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the world’s largest independent omnichannel sell-side advertising platform, today announced the acquisition of Carbon, a platform that enables publishers to measure, manage and monetize audiences in real-time. As the industry prepares for the deprecation of third party cookies and other third party identifiers, the acquisition accelerates Magnite’s seller-first, privacy-focused identity and audience solutions focused around first-party segments and bolsters the Product and Engineering teams in this critical area. The acquisition was completed through an asset purchase and financial terms were not disclosed. “We believe seller-defined audiences will be a core part of the future of identity...

Continue reading

ASANTE GOLD COMMENCES MINING AT BIBIANI, GHANA

Vancouver, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) — Asante Gold Corporation (CSE:ASE/ FRANKFURT:1A9/U.S.OTC:ASGOF) (“Asante” or the “Company”) is pleased to announce that following a successful Public Hearing, the Company has received the updated Environmental and Mine Operating Permits necessary to commence open pit mining activities at Bibiani, Ghana’s newest mine.   Open Pit Mining Operations have started, with focus on delivery of ore from the Strauss and Walsh satellite pits. The #1 Cutback at the Main Pit has also started. Refurbishment of mine haulage roads, safety berms, waste dumps and mining benches are advanced. First ore has been delivered to the Run of Mine Pad, more than one month ahead of schedule. Receipt of these permits follow an extensive process of scoping studies, presentation and detailed review...

Continue reading

Koios Beverage Corp. Announces Non-Binding Letter of Intent to Acquire Retox Beverage Corp.

DENVER and VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) — Koios Beverage Corp. (CSE: FIT; OTC: FITSF) (the “Company” or “Koios”) is pleased to announce that it entered into a non-binding letter of intent dated February 27, 2022 (the “LOI”) with Retox Beverage Corp. (“Retox”) in respect of a proposed transaction (the “Proposed Transaction”), whereby the Company would acquire all of the issued and outstanding securities of Retox by way of a three-cornered amalgamation. Retox is a privately held beverage company that is focused in the production of creative soft beverages, sodas and seltzers. The Proposed Transaction The Proposed Transaction is expected to be structured as a three-cornered amalgamation, pursuant to which a wholly-owned subsidiary to be incorporated by the Company...

Continue reading

Intema closes Parabellum Media acquisition

This acquisition will strengthen Intema’s esports operations with the addition of the Parabellum Esports professional team, a two-time champion on the NACL circuit, including a top-12 global finish at the 2021 Rainbow Six Invitational.Intema is also building training capabilities for future esports players with the Northern Shield Academy.Parabellum Media has competitive rosters in Rainbow Six, Rocket League, CSGO and iRacing, supported by a team of 10 content creators, with social media reach of over 300,000 followers.MONTREAL, Feb. 28, 2022 (GLOBE NEWSWIRE) — Intema Solutions Inc. (“Intema” or the “Corporation”) (TSXV: ITM, OTCMKTS: ITMZF) is pleased to announce that it has closed the agreement announced on December 8, 2021 with Amuka Ventures Inc. (doing business as Amuka Esports) to acquire all of the outstanding...

Continue reading

Astec Reports Fourth Quarter 2021 Results

Fourth Quarter 2021 Highlights (all comparisons are made to the prior year fourth quarter):Net Sales increased 12.1% to $267.8 million Gross Profit Margin of 20.1% decreased 370 bps Net Income decreased 159.7% to a loss of $9.2 million; Adjusted Net Income of $(0.6) million decreased 104.7% from $12.8 million Diluted EPS of $(0.40) compared to $0.67; Adjusted EPS of $(0.03) decreased from $0.56 Record Backlog of $762.6 millionCHATTANOOGA, Tenn., Feb. 28, 2022 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced today its financial results for the fourth quarter of 2021. Fourth quarter of 2021 net sales of $267.8 million increased 12.1% compared to $238.9 million for the fourth quarter of 2020. Domestic sales increased $32.9 million or 18.2% due mainly to stronger asphalt plant and concrete plant sales as well...

Continue reading

Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022Phase 1 trial of KB407 in cystic fibrosis patients in Australia expected to begin in 1H 2022; IND filing and U.S. trial initiation anticipated in 2H 2022Jeune Aesthetics on track to announce Phase 1 proof-of-concept efficacy data from KB301, being developed for aesthetic indications, in 1Q 2022Strong balance sheet with December 31, 2021 cash, cash equivalents and investments of $502.5 millionPITTSBURGH, Feb. 28, 2022 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal” or the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational updates for the fourth...

Continue reading

ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided clinical development and operational highlights. “ALX Oncology achieved key milestones in 2021 to advance our lead program, evorpacept, a next-generation CD47 blocker, through multiple clinical trials,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “Notable accomplishments included initiating two Phase 2 trials in head and neck squamous cell carcinoma (“HNSCC”) and presenting encouraging Phase 1b data from the ASPEN-01 trial in gastric/gastroesophageal junction (“GEJ”)...

Continue reading

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “It has been an exciting time for Arvinas over the past 12 months, including the beginning of a transformational collaboration with Pfizer, and compelling clinical updates supporting our two lead clinical programs, ARV-471 and bavdegalutamide, or ARV-110,” said John Houston, Ph.D., chief executive officer and president at Arvinas. “We believe ARV-471 has the potential for a best-in-class profile for the treatment of ER+/HER2- breast cancer and, looking ahead, we have a number of important clinical milestones upcoming...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.